The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
150
Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
UMC Ljubljana, Department of Infectious Diseases
Ljubljana, Slovenia
RECRUITINGinflammatory proteins in erythema migrans patients
The inflammatory immune profiles will be assessed using Luminex to measure the expression of cytokines and chemokines representative of innate and adaptive TH1, TH2, TH17, and B cell responses in serum and if available, skin, of patients during active infection and after treatment.
Time frame: up to 12 months follow-up
gene polymorphisms in erythema migrans patients
The expression of disease-relevant genomic variants will be assessed using ImmunoChip.
Time frame: at enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.